updated Sun. March 24, 2024
-
Market Realist
February 23, 2018
Eli Lilly and Company's (LLY) human pharmaceutical business also includes oncology products Alimta, Cyramza, Erbitux, Gemzar, Lartruvo, Portrazza, and its new product, Verzenio. In 4Q17, oncology revenue was driven by strong performance by Erbitux, Cyramza, Lartruvo, and Gemzar, and partiallyÃÂ ...
24/7 Wall St.
February 9, 2018
The product portfolio includes Zyprexa (for schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder), Erbitux (cancer) and Alimta (chemotherapy). Eli Lilly also has a strongÃÂ ...
Facts of Week
February 6, 2018
Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung. Itis the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. American Lung Association has estimated that around 224,210new cases were diagnosedÃÂ ...
Facts of Week
February 5, 2018
Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung. Itis the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. American Lung Association has estimated that around 224,210new cases were diagnosedÃÂ ...
Market Realist
February 1, 2018
In 4Q17, Celgene's (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis. In 4Q17, Abraxane's quarter-over-quarter revenues remained flat. In 4Q17, in the US market and international market, Abraxane generated revenues of $155 millionÃÂ ...
MilTech
January 14, 2018
The report gives the clear idea on the country wise DMF filed by worldwide companies related to the Gemzar. The report also highlights the patent details of Gemzar. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis byÃÂ ...
Market Realist
January 10, 2018
Perjeta's peers include Novartis's (NVS) Tykerb, Puma Biotechnology's (PBYI) Nerlynx, Celgene's (CELG) Abraxane, and Eli Lilly's Gemzar. The growth in sales of Perjeta could boost the Vanguard International Dividend Appreciation ETF (VIGI). Roche and Novartis make up about ~2.7% and 2.8% of VIGI'sÃÂ ...
Ovarian Cancer News Today
December 18, 2017
Researchers discovered how AB Science's therapy masitinib — a veterinary medicine sold as Kinavet in the U.S. — acts to re-sensitize drug-resistant tumor cells to the anti-cancer treatment Gemzar (gemcitabine). The discovery could lead to better treatments for diseases where nucleoside analogues likeÃÂ ...
Market Realist
December 7, 2017
In 3Q17, Eli Lilly's (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets (outside US markets), Alimta generated revenues of $260.3 million and $254.2 million,ÃÂ ...
Breast Cancer News
May 3, 2016
Gemcitabine was approved by the US Food and Drug Administration (FDA) on May 19, 2004, and it is commercialized under the brand name Gemzar by Eli Lily and Company. While approved for numerous other indications, in the case of breast cancer, gemcitabine is indicated to be used in combinationÃÂ ...
Medical News Today
October 9, 2013
The randomized trial investigated treatment with gemcitabine (a chemotherapy drug marketed in the US under the brand name Gemzar) given in addition to surgery, comparing this with observation alone, and the results are published in the journal JAMA. The authors conclude that treatment with adjuvantÃÂ ...
The Financial
December 31, 1999
“Gemzar Drug Insights, 2018-2020” Market report highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers byÃÂ ...
Market Realist
December 31, 1999
In 4Q17, Celgene's (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis. In 4Q17, Abraxane's quarter-over-quarter revenues remained flat. In 4Q17, in the US market and international market, Abraxane generated revenues of $155 million and $96 million,ÃÂ ...
Market Realist
December 8, 2017
In 3Q17, Eli Lilly's (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets (outside US markets), Alimta generated revenues of $260.3 million and $254.2 million, ...
The Donohue Report
December 7, 2017
Some of the major drugs in this market are Irinotecan liposome (Onivyde), Docetaxel (Taxotere), Paclitaxel (Taxol), Cisplatin, Capecitabine (Xeloda), Albumin-bound paclitaxel (Abraxane), Oxaliplatin (Eloxatin), Irinotecan (Camptosar), 5-fluorouracil (5-FU), and Gemcitabine (Gemzar). The global pancreatic ...
MilTech
December 6, 2017
In addition, increasing healthcare awareness is also fuelling the growth of global ovarian cancer market. However, subsequent launch of generic drugs and patent expiration of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of the major factors restraining the growth for global ...
Medgadget (blog)
November 19, 2017
Gemzar Drug Insights, 2017 highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Gemzar covering the historical global sales and also provides the Gemzar sales estimation during the ...
Dublin City University
November 17, 2017
This week, to mark World Pancreatic Cancer Day Dr Sandra Roche of the National Institute of Cellular Biotechnology wrote about the work carried out by the Pancreatic Cancer Research Group, NICB, DCU. The Pancreatic Cancer Research Group is comprised of lab based researchers who collaborate ...
NB Herard
November 13, 2017
Earlier studies showed RX-3117 to be superior to Gemzar, made by Eli Lilly (NYSE:LLY) and used in pancreatic cancer. Gemzar, like Abraxane, is considered a standard of care for this lethal disease but Gemzar leads to resistance in patients at an unacceptable rate of 25% of the time, with only a paltry 5%Â ...
Fred Hutch News Service
November 9, 2017
In a study published earlier this year, he observed that 20 different cell lines from pancreatic cancer patients all responded to the chemotherapy drug gemcitabine (Gemzar) in a laboratory setting, but most patients did not respond in the clinical setting. He went on to discover the reason why: tumor cells in ...
Market Realist
October 13, 2017
In 1H17, Gemzar reported revenues of ~$53.6, compared with $61.5 million in 1H16. In 2Q17, Gemzar generated revenues of around $27.8Â ...
MedPage Today
October 11, 2017
It resumed in April 2012 with NPBC amended to include topotecan, gemcitabine (Gemzar) or any other drug approved in this setting. After three ...
Medgadget (blog)
October 10, 2017
Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of ...
Inside INdiana Business
October 10, 2017
He is credited with successfully guiding Lilly through the patent expirations for four of its main products (Gemzar, Zyprexa, Cymbalta and Evista)Â ...
MilTech
October 9, 2017
The pancreatic cancer therapeutics market is dominated by Gemzar (Gemcitabine) developed by Eli Lilly. Gemzar is indicated as first-line ...
Ars Technica
September 17, 2017
This is a drug used to treat pancreatic, lung, breast, and bladder cancers and is often sold under the brand name Gemzar. The researchers suspected that some of the cells may secrete a drug-busting molecule. So they tried filtering the cell cultures to see if they could catch it. Instead, they found that the cell ...
Breast Cancer News
May 3, 2016
Gemcitabine is a chemotherapy drug classified as anti-cancer, antineoplastic or cytotoxic. It is also included in the group of drugs called ...
MilTech
December 31, 1999
Gemzar and Tarceva (Erlotinib) by Genentech/OSI Pharmaceuticals/Roche account for a majority share of the global pancreatic cancer therapeutics market as these drugs have been in the market for a considerable time. Abraxane by Celgene is another therapeutic drug that was launched in the U.S. and ...
MilTech
December 31, 1999
Moreover, high adoption of premium-priced drugs such as Abraxane injection and Gemzar to treat the pancreatic cancer boost the market.
Medgadget (blog)
December 31, 1999
Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of ...
Nasdaq
December 31, 1999
The company's portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta ...
Coventry Telegraph
September 20, 2017
Patients will be treated with two existing chemotherapies, nab-paclitaxel (Abraxane) and gemcitabine (Gemzar), in combination with a newÃÂ ...
Ars Technica
September 17, 2017
This is a drug used to treat pancreatic, lung, breast, and bladder cancers and is often sold under the brand name Gemzar. The researchersÃÂ ...
Medgadget (blog)
September 12, 2017
Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some ofÃÂ ...
BioPharma Dive
September 7, 2017
... the depression treatment Cymbalta (duloxetine), the erectile dysfunction drug Cialis (tadalafil), cancer drug Gemzar (gemcitabine) and ADHDÃÂ ...
FierceBiotech
September 6, 2017
The anticipated haul will fund late-phase trials of NuCana's reformulated cancer candidates, including a version of Eli Lilly's Gemzar it hopesÃÂ ...
Medgadget (blog)
September 4, 2017
Based on chemotherapy, the global lung cancer therapeutics market can be categorized into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine,ÃÂ ...
News-Medical.net
August 11, 2017
Gemcitabine (Gemzar): Ribonucleotide reductase is inhibited and it fights with deoxycytidine triphosphate to fit itself into the DNA. After theÃÂ ...
Transcript Daily
July 28, 2017
Products like Zyprexa, Cymbalta, Evista, and Gemzar are all facing declining sales due to generic competition. In 2017, Eli Lilly is expected toÃÂ ...
Nasdaq
July 25, 2017
The company's portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), CymbaltaÃÂ ...
www.oncnursingnews.com/
July 25, 2017
According to O'Shaugnessy, gemcitabine (Gemzar) plus carboplatin has been historically used as the doublet of choice in those patients.
Digital Journal
July 21, 2017
Based on chemotherapy, the global lung cancer therapeutics market can be categorized into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine,ÃÂ ...
ModernMedicine
July 10, 2017
... or occasionally recurrent bladder cancer, a single post-transurethral resection of bladder tumor (TURBT) instillation of gemcitabine (Gemzar)ÃÂ ...
Mesothelioma.net Blog (blog)
July 9, 2017
Gemzar is a brand name chemotherapy drug made by Eli Lilly with the generic name gemcitabine. It has been approved and in use for more than 20 years but isÃÂ ...
Immuno-Oncology News
September 19, 2016
In this randomized, open-label, Phase 2 clinical trial (NCT01303172), researchers examined the safety and tolerability of IMM-101 plus GemzarÃÂ ...
Breast Cancer News
May 3, 2016
Gemcitabine is a chemotherapy drug classified as anti-cancer, antineoplastic or cytotoxic. It is also included in the group of drugs calledÃÂ ...
Medical News Today
October 9, 2013
The randomized trial investigated treatment with gemcitabine (a chemotherapy drug marketed in the US under the brand name Gemzar) givenÃÂ ...
WallStreetPR
December 31, 1999
... in oncology management and has successfully launched various multi-billion dollar brands including the Gemzarî, Alimta,î and Erbituxî.
MilTech
December 31, 1999
However, subsequent launch of generic drugs and patent expiration of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin areÃÂ ...
MedPage Today
March 27, 2017
The guidelines also list paclitaxel (Taxol) or docetaxel (Taxotere), gemcitabine (Gemzar), and pemetrexed (Alimta) as possible second-line options in this patient population.
|
news and opinion
|
